A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Recruiting

Phase 2

NovoTTF-200T & Gemcitabine, Nab-PaclitaxelA Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Sponsor:

Ashish Manne

Code:

NCT05624918

Conditions

Pancreatic Adenocarcinoma

Resectable Pancreatic Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Nab paclitaxel

Gemcitabine

NovoTTF-200T(P)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-29. This information was provided to ClinicalTrials.gov by Ashish Manne on 2025-07-31.